Analytical Data
-
基因名
Integrin alpha 10 beta 1
- Application
-
别名
ITG-A10
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
E9Q6R1
-
表达区间
Glu919~Phe1088
-
分子量
20kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Integrin alpha 10 beta 1 is a critical receptor involved in various cellular processes, including cell adhesion, migration, and signaling. It primarily interacts with extracellular matrix (ECM) components, playing a significant role in tissue development and repair. Research has shown that this integrin is particularly important in the context of cartilage and bone, where it contributes to the maintenance of the structural integrity of these tissues. Abnormalities in integrin alpha 10 beta 1 expression or function have been linked to a range of pathological conditions, including osteoarthritis and other related bone disorders. The study of recombinant integrin alpha 10 beta 1 protein is essential for understanding its molecular mechanisms and biological functions. By producing this recombinant protein in laboratory settings, researchers can explore its interactions with ECM components and other signaling pathways. This knowledge could lead to the development of targeted therapies for diseases associated with integrin malfunctions. Additionally, the generation of monoclonal antibodies against this integrin could provide valuable tools for diagnostic and therapeutic applications. As such, the research surrounding integrin alpha 10 beta 1 not only enhances our understanding of cell-matrix interactions but also holds potential for clinical advancements in regenerative medicine and tissue engineering.
